Hydrogen sulfide (H 2 S), together with nitric oxide (NO) and carbon monoxide (CO), belongs to the gasotransmitter family and plays important roles in mammals as a signaling molecule. Many studies have also shown the various therapeutic effects of H 2 S, which include protection against myocardial ischemia injury, cytoprotection against oxidative stress, mediation of neurotransmission, inhibition of insulin signaling, regulation of inflammation, inhibition of the hypoxia-inducible pathway, and dilation of blood vessels. One major challenge in the development of H 2 S-based therapeutics is its delivery. In this manuscript, we assess the various drug delivery strategies in the context of being used research tools and eventual developability as therapeutic agents.
INTRODUCTION
Hydrogen sulfide (H 2 S) is most widely known as a poisonous gas with the smell of rotten eggs. However, research in recent years has convincingly demonstrated the role of H 2 S as an endogenous gasotransmitter with importance on par with that of nitric oxide (NO) and carbon monoxide (CO). 1, 2 H 2 S has been shown to have anti-inflammation, [3] [4] [5] [6] [7] antitumor, [8] [9] [10] [11] [12] ion channel regulation, [13] [14] [15] [16] cardiovascular protection, [17] [18] [19] [20] [21] and antioxidation effects. 22, 23 Along with these physiological roles, H 2 S is emerging as a potential therapeutic agent much the same way as NO 24, 25 and CO. 26 There have been numerous research publications demonstrating the tremendous therapeutic potential of H 2 S, and some high-quality reviews also addressed the same point. 3, [27] [28] [29] [30] [31] [32] [33] Thus there is no need to comprehensively summarize the literature here. Instead, this article will focus on examining critical remaining issues to address in the coming years in developing H 2 S-based therapeutics. With the demonstrated therapeutic effect, the development of H 2 S-based therapeutics relies on the ability to deliver hydrogen sulfide to the desired location(s), at the appropriate concentrations, and with the appropriate pharmacokinetics. Because H 2 S is an endogenous gaseous signaling molecule, it is recognized that low levels of H 2 S (nanomolar) may be tolerated indefinitely. 34 On the other hand, it is commonly accepted that H 2 S dose-response curves are generally bell shaped with a very narrow therapeutic window. 35 Thus delivery of precisely controlled doses is a critical issue in the development of H 2 S-based therapeutics. Direct inhalation obviously would not be an acceptable approach for many reasons including smell, irritation, enhanced local concentrations at the first point of administration (lung), difficulties in controlling dosage, and dependence on patient's lung functions and physical states. Some of the same issues are true with simple administration of fast-releasing H 2 S donors such as NaHS and Na 2 S. In addition, H 2 S has many unique properties, which present a special set of challenges in the development of therapeutics. Below we discuss such issues in detail before the introduction of the various drug delivery approaches. Subsequent discussions of H 2 S-based therapeutics are in the context of the unique properties of H 2 S.
THE HOMEOSTASIS OF HYDROGEN SULFIDE AND ITS PHARMACOLOGICAL EFFECT
To appropriately discuss delivery and developability issues, it is important to understand the fundamentals of hydrogen sulfide homeostasis in normal physiology. Very different from most other signaling molecules is the chemical properties of H 2 S, which contribute to its biological activities and homeostasis. For example, most signaling molecules that act on receptors and/or enzymes do so by simple binding without chemical reactions. However, for H 2 S, its chemical reactivity is an important part of its biological functions and fate. Thus any analysis of H 2 Sbased therapeutics needs to take into consideration its unique properties and reactivity. H 2 S is a small molecule, slightly larger than water with the following properties: (1) acidity, (2) reducing ability, (3) high affinity to iron-containing molecules such as heme, (4) easy convertibility among species of different oxidation states, (5) polymerizability and existence in various oligomeric states, (6) volatility, and (7) high water solubility (up to 80 mM at 37°C 36 ). Specifically, H 2 S is a weak acid with pK a values (37°C) for the first and second dissociation steps being around 6.88 and 19, respectively. 37 Thus under physiological conditions (pH 7.4), H 2 S largely exists in two forms: the neutral molecular form (H 2 S) and the monoionized form (HS − ). Sulfide (S 2− ) is a very minor component simply because of the second pK a being very high. Further complicating the picture is the fact that hydrogen sulfide, and its oxidized forms such as SO 2 38, 39 and persulfide [40] [41] [42] [43] may all have their own biological activities. Thus detailed mechanistic understanding will depend on the ability to deliver a "clean" species with well-defined concentration and delivery rates. Some of these issues are discussed in various sections below. nervous system and liver, and CSE activity being higher than CBS activity in the aorta, portal vein, and other vascular tissues. 48 3MST is expressed in the central nervous system, mostly in glial cells, hippocampal pyramidal neurons, cerebellar Purkinje cells, and mitral cells in the olfactory bulb. In addition to the expression and distribution of these enzymes, endogenous production of H 2 S also depends on availability of substrates and enzyme activity, which might be affected by many properties of the intracellular environment such as the redox state. H 2 S is metabolized via the sulfide oxidation pathway in the mitochondria. [49] [50] [51] Basically, a membrane-bound sulfide:quinone oxidoreductase (SQR) oxidizes H 2 S to a SQR-persulfide intermediate. In the presence of O 2 and water, sulfur dioxygenase (SDO) oxidizes the persulfide intermediate to sulfite. [52] [53] [54] Then rhodaness transfers a sulfane sulfur (SQR persulfide) to sulfite to form thiosulfate (S 2 O 3 −2 ) 55 (Fig. 2) , which reacts with glutathione (GSH) via catalysis by thiosulfate sulfurtransferase (TST) to produce GSH persulfide (GSSH). Subsequently, GSSH is used as a substrate by SDO to generate sulfite, which is further metabolized to sulfate by sulfite oxidase (SO). In addition, H 2 S can be converted to dimethylsulfide by cytosolic methylation. Another possible pathway for H 2 S removal is related to the interaction of H 2 S with myoglobin (Mb) and hemoglobin (Hb) to form the sulfheme complex. [56] [57] [58] One cannot help but wonder whether the various intermediates have their own regulatory roles, which would be a good reason for nature to use such a complex transformation process.
Besides the enzymatic regulation of H 2 S production and metabolism, H 2 S could also be stored in proteins by forming persulfide through persulfidation (S-sulfhydration). [59] [60] [61] Most, if not all, S-sulfhydration occurs at reactive cysteine residues in proteins and results in the conversion of the thiol (-SH) group of a cysteine to a persulfide group (-SSH) , which is also the major pathway of sulfide signaling. 59, 60, [62] [63] [64] The formation of persulfide in cysteine residues of a protein can cause structural changes, which alter protein activity and lead to a cellular and physiological responses to H 2 S. For instance, in 2011, Mustafa et al. observed that S-sulfhydration of Cys-43 in the Kir 6.1 subunit of the ATP-sensitive potassium channels (K ATP ) reduces ATP binding and enhances phosphatidylinositol 4,5-bisphosphate (PIP 2 ) binding, which leads to K ATP channel activation. 65 S-sulfhydration of the calcium-dependent intermediate conductance potassium channel (IKca) contributes to H 2 S-dependent hyperpolarization of endothelial cells. All these findings indicate that H 2 S is an important endothelial-derived hyperpolarizing factor (EDHF) and dysregulation of the pathway may be a critical factor in the development of vascular diseases such as hypertension. As an additional example, in 2013 Yang and coworkers 66 demonstrated that S-sulfhydration of Kelch-like ECH-associated protein 1 (Keap1) at Cys-151 enhances nuclear translocation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), antioxidant gene transcription, and GSH production, and thus protects cells from oxidative stress and premature senescence. These findings point to an important function of H 2 S against cellular aging via the posttranslational modification of the Keap1/Nrf2 axis and associated oxidative stress. All these studies show that persulfide formation is a posttranslational modification of the cysteine residue. However, it needs to be noted that the sulfur atom of H 2 S as well as thiols (R-SH) possesses the same oxidation state (-2); thus direct persulfide formation via H 2 S is not possible. There are two proposed persulfide formation mechanisms. One is the addition of SH − to a sulfenic (S-OH) group in proteins to form persulfide. Since protein thiolate (R-S − ) is a strong nucleophile, it readily reacts with H 2 O 2 to yield the corresponding sulfenic group, which, in turn, reacts with SH − to yield the corresponding persulfide. 67, 68 The other mechanism relies on polysulfides. Some recent studies showed that polysulfides can be synthesized endogenously by 3MST, [69] [70] [71] and are much more potent in inducing persulfide formation.
Sulfide-hemeprotein interactions are also involved in sulfide signaling. Sulfide has strong affinity for hemeproteins such as cytochrome c oxidase (CcO), Mb, and Hb, and can convert the high spin ferric center of heme protein to a low spin ferric-sulfide complex, reducing the central metal from the ferric to ferrous state, or forming ferrous-sulfide complexes. The effects of sulfide on hemeproteins are concentration-dependent. For example, at high concentrations, H 2 S binds directly to the ferric heme α3 center and completely inhibits CcO activity, leading to inhibition of the mitochondrial respiration and subsequent toxicity; however at low concentrations (nearly stoichiometric), H 2 S stimulates O 2 consumption without having an inhibitory effect. 72 There have been studies 73 showing that the interaction of H 2 S with hemeproteins would decrease cellular ATP concentration and activate K ATP channels. These interactions can also regulate the function of hemeproteins, produce bioactive sulfide metabolites, and protect against hemeinduced oxidative stress, which plays an important role in sulfide signaling. All indications are that the redox chemistry of H 2 S and its affinity to iron are the key characteristics that contribute to its biology.
B. Current Challenges
It is clear that there is growing understanding of sulfide signaling pathways and its various biological effects including the relaxation of blood vessels, cytoprotection against oxidative stress, and anti-inflammatory actions that would warrant significant efforts in translating the known pharmacological effects of H 2 S to the development of H 2 S-based therapeutics. A major issue is the development of H 2 S donors or prodrugs as potential therapeutics. This is because there are obvious concerns with using H 2 S or its salt forms. For example, the volatile nature and stench odor make H 2 S or its salts very unlikely delivery forms for pharmaceutical uses. Beyond the superficial, there are also mechanistic reasons for the development of donors and prodrugs that can afford sustained release of H 2 S. First, as discussed above, the dose-response curves in almost all known pharmacological experiments for H 2 S are bell-shaped with a narrow therapeutic window. Thus there is a need to deliver precise amounts of H 2 S. However, there are complex processes of maintaining H 2 S homeostasis in living system and H 2 S is volatile. Thus bolus administration of H 2 S would only lead to a spike of H 2 S concentration. Although there have been no systematic studies of the effect of duration of H 2 S treatment, one can assume that a sustained and constant level of H 2 S for certain duration would be far more desirable than a quick spike for therapeutic applications. Second, much of hydrogen sulfide's effect resides with its redox chemistry. A quick bolus administration of H 2 S is likely to change the cellular redox states and the effect may go well beyond H 2 S-specific functions. Third, at high H 2 S concentrations after bolus administrations, the distribution of various sulfur species may be very different from that of the physiologic state. It is well known that persulfide species may have activities of their own. 70, 74 Some studies already showed that polysulfides formed in solutions of H 2 S mediate protein thiol oxidation, which converts cysteinyl thiolates (Cys-S − ) to persulfides (Cys-S-S − ). 70 There are suggestions that polysulfides/thiosulfates rather than H 2 S itself are the actual active molecules responsible for persulfide formation, and thus mediate sulfide signaling. 70 Depending on the release rates and their own oxidation states, using different H 2 S donors at the same concentration might lead to the generation of different concentrations of various sulfur species. Thus this change in distribution could make mechanistic studies very hard, or even physiologically irrelevant. Meanwhile, "pure" polysulfide donors are highly desired in this field, but it is still quite a challenge for synthetic chemists to make such molecules at high purity. Another difficulty in H 2 S research is the lack of understanding of the ideal concentration of H 2 S in physiology and in therapy, including the question of the normal endogenous H 2 S concentration range in circulation. This is largely due to the lack of sensitive methods for the detection of H 2 S and the lack of H 2 S donors with well-defined release rates that would allow a detailed examination of the H 2 S concentration-effect relationship issue. Although there are many methods for detecting H 2 S including the colorimetric methylene blue (MB) method, ion-selective or polarographic electrodes, gas chromatography with flame photometry, the monobromobimane assay, and assays using various fluorescent probes, 75, 76 none quite comes to the needed sensitivity and response time for the near real-time detection of H 2 S at physiological concentrations. A wide physiological concentration range has been reported: from 0.1 μM to more than 300 μM. 3 As a conservative estimate, plasma H 2 S levels in healthy humans or animals might be in the high nanomolar to low micromolar range. 3 The lack of methods for accurately monitoring H 2 S levels in circulation or in the targeted organs and systems makes it hard to estimate the therapeutic dosages. Thus prodrugs, which directly release H 2 S without involving redox chemistry, will be important research tools for dissecting many of the remaining issues.
Even in developing H 2 S prodrugs, there are unique challenges as compared to prodrugs of other small molecules. Much of these challenges are associated with H 2 S's volatility and rapid metabolism. For example, for a prodrug of a small molecule drug with a half-life in hours, the dosage of the prodrug can be easily translated into a stoichiometric concentration because the drug released would persist within the circulation for a reasonable period of time. However, for a gasotransmitter, this is very different. Because of its volatility and thus its constant evaporation/exhalation, H 2 S concentration is a balance between exhalation and production. If one takes into consideration the cellular metabolism of H 2 S, then it becomes easy to understand why the concentration of the administered prodrug may not have a linear relationship with H 2 S concentration. In one study, it was found that for a series of H 2 S prodrugs with different release rates at 200 μM, the highest peak H 2 S concentration achieved was only 50% of the prodrug concentration in a solution experiment when the release half-life is short (13 min). 77 Then the concentration quickly drops. On the other hand, another prodrug in the same series with a slower release rate (t 1/2 , 100 min) provided a sustained concentration of H 2 S at 5% of its prodrug concentration for over 1 hr. Therefore, one can see that H 2 S prodrug release rate plays a very important role in determining the concentration of the drug. In addition, to address the biological effect of H 2 S prodrugs, well-defined control compounds are also necessary. With polysulfide compounds, this is hard to achieve.
C. Developability Issues Related to H 2 S Donors or Prodrugs
In drug discovery and development, assessing developability is a critical step. [78] [79] [80] Prodrugs are no exceptions, 81 however, with unique features, which are discussed in later sections. Drug developability is a complex issue; it is well known that there are many examples of drugs in the market that do not fit the model of modern day criteria. Nevertheless, literature developability criteria are very important reference points. When judgment calls are made, there is a need to have a clear understanding of why one needs to deviate from the "standard" developability criteria.
In assessing drug developability, one typically needs to consider pharmacokinetics, metabolism, permeability, protein binding, toxicity, efficacy, chemical tractability, and drugdrug interactions, among other important factors. 78, 79 When it comes to criteria that can guide the design of new chemical entities (NCE), there are many specific factors to consider. The most well-known is the Lipinski's "Rule of Five." When it comes to specific molecular properties to assess, experiments commonly include determinations of solubility, stability, membrane permeability, p450/microsomal metabolism, cytotoxicity, mutagenicity, hERG inhibition (cardiotoxicity), p450 inhibition and induction, and protein binding.
In applying drug developability assessment to a prodrug project, there are unique issues to consider. This is especially true for prodrugs of a gasotransmitter. First, the potency and efficacy issues are no longer the same as in a typical small molecule drug discovery project. This is because the active drug itself is already fixed. In the case of hydrogen sulfide, its potency and efficacy are defined by the parent drug already. Second, for a gasotransmitter prodrug such as H 2 S, the drug permeability issue is very different from that of a typical small molecule drug. The prodrug itself actually does not necessarily need to penetrate any barrier as long as the parent drug can reach the site of action. With a gasotransmitter, the parent drug itself is very permeable across cellular barriers. Thus the prodrug does not even need to get into the intracellular space in order to be effective. In a way, sometimes it might be preferred that the prodrug not get into the cell in order to minimize side effect and toxicity issues. This aspect is very different from that of a traditional small molecule drug discovery project. Another unique issue for a prodrug of a gasotransmitter is the dose-response issue. As discussed above, the relationship between the drug effective dose and the prodrug dose is not necessarily a linear relationship because of the volatility and rapid metabolism of H 2 S. The relationship among release rates, volatility, and rate of metabolism defines the "steady state" concentration, if any. Thus having well-defined release rates is very important for the future development of H 2 S prodrugs. Additional developability issues unique to hydrogen sulfide include odor and ready interconversions of various species. The first would be expected to significantly affect patient compliance, dispensing, and storage; and the second would be expected to affect chemical tractability in process chemistry, quality control, dosage determination, and the overall approval process by the US Food and Drug Administration (FDA). Thus developing prodrug forms that can overcome these issues are also very critical to the future of H 2 S-based therapeutics. The following sections discuss the current state of the field in the context of these developability issues.
HYDROGEN SULFIDE PRODRUGS AND DELIVERY APPROACHES
With the above discussions of developability issues and associated challenges, we layout some ideal characteristics of H 2 S donors or prodrugs for therapeutic applications (Fig. 3 ), which could serve as reference points in evaluating existing donors and in guiding future efforts. First of all, tunable and controllable H 2 S release rates are essential properties. The release rate of H 2 S prodrugs directly affects the effective concentration of the parent drug and thus their functions. Therefore, designing H 2 S prodrugs with a range of controllable release rates is highly desired. Along this line, the use of well-defined triggering mechanisms for release will be very much desired for certain applications. Second, stability during storage, drug preparation, or formulation is required. Third, water solubility is essential for the eventual drug delivery and absorption. It is well known that drugs need to have certain water solubility in order to be absorbed and to be effective. 80 Water solubility is also an important factor that could affect formulability and pharmacokinetic issues. Fourth, chemical tractability is critical to all small molecule drugs. The ability to prepare and characterize the prodrug with sufficient purity and well-defined distribution of various species is critical to the viability of a drug discovery and development project. Fifth, the presence of aversive odor and taste is a developability issue for all drugs. This issue is especially prominent with H 2 S prodrugs because of its known unpleasant odor, which is expected to not only affect patient compliance, but also storage and delivery. Thus finding ways to ameliorate the undesirable odor will be important. Lastly, unique to prodrug development is the issue of tractability of the side product(s) after drug release from the prodrug. This issue is important at the research stage so that there is a proper control compound. More importantly, at the clinical development stage there needs to be a good understanding of the chemical species introduced into the human body and a reasonable level of assurance that the "side product(s)" does not have undesirable effects. The following discussions examine various available delivery forms of H 2 S prodrugs in the context of suitability for and limitations in therapeutic applications (Table I) .
Ideal H 2 S prodrugs

A. H 2 S Gas
Following the report by Abe and Kimura 82 in 1996 on the possible role of endogenous hydrogen sulfide as a neuromodulator in the brain, a surge of research activities probing the physiological function of hydrogen sulfide 83 has ensued, shedding light on the biological roles of hydrogen sulfide. Crucial in these biological studies as well as in the attempt to make hydrogen sulfide based therapeutics is the use of the appropriate hydrogen sulfide equivalents, donors, or prodrugs that supply hydrogen sulfide to the target location at the right concentration. Interestingly, it has been shown by Roth and co-workers that direct exposure of mice to around 80 ppm of hydrogen sulfide gas induces a state of hypothermia or suspended animationlike state. 84 Five minutes after exposure to this concentration, oxygen consumption dropped by about 50% while carbon dioxide output dropped by 60%. Longer exposure time (6 hr) led to a 90% drop in metabolic rate, followed by a reduction of core body temperature to 2°C above ambient temperature, as well as a decrease from around 120 breaths per minute to less than 10 per minute. Remarkably, upon exposure to fresh air and ambient temperature, the metabolic rate and core body temperature of the treated mice also returned to normal without any apparent behavioral or functional changes. 73, 84 Taking it further, Blackstone and Roth demonstrated that mice under a suspended animation-like state brought about by a 20-min pretreatment with hydrogen sulfide gas can survive for more than 6.5 hr in an environment with only 5% oxygen without any manifestation of detrimental effects. 85 This ability to control the induction of hypothermia should be useful in surgery, organ preservation, ischemia, pyrexia, reperfusion, etc. 84, 85 Unfortunately, these findings were not successfully translated to other mammals such as sheep and piglets. 30 Nevertheless, these experiments demonstrate that H 2 S can be used under certain well-controlled conditions. Notwithstanding, the direct use of hydrogen sulfide gas in biological studies and as a therapeutic agent proved to be less than ideal. Mathai and co-workers showed in 2009 that hydrogen sulfide gas is permeable across epithelial barriers, endothelial barriers, and membrane rafts through simple diffusion without the need of membrane channels. 86 Despite its permeability, it is very challenging to study the pharmacokinetics of hydrogen sulfide gas due to the inherent difficulty of controlling H 2 S's exact concentration, arising from its volatility and high reactivity within the biological matrix. 87 Another significant limiting factor in using hydrogen sulfide gas in both research and medical settings is its unpleasant odor and the use of elaborate equipment such as fume cupboards, deoxygenated tubings, and trapping solutions. 37 As a result, the search for pharmaceutically acceptable forms of hydrogen sulfide donors seems to be the only viable way for the further development of H 2 S-based therapeutics.
B. Sulfide Salts
The first hydrogen sulfide donor compounds employed as exogenous sources in biological experiments were the inorganic sulfide salts (i.e., Na 2 S, NaHS, CaS). Solutions of these inorganic sulfides can be prepared from hydrates of sodium hydrogen sulfide (NaHS.xH 2 O), the nonahydrate disodium salt (Na 2 S.9H 2 O), or the anhydrous form. Upon dissolution in water, these salts establish an equilibrium among S 2− , HS − , and H 2 S, the ratio of which depends on temperature, pressure, and pH. Under physiological conditions, HS − / H 2 S ratio is about 3:1.
With the use of these inorganic sulfide salts as hydrogen sulfide donors, various therapeutic and pathological effects of H 2 S have been studied over the years. An excellent overview of both the protective and pathological effects of NaHS as a hydrogen sulfide donor in different animal models was published by Szabo 31 in 2007. Protective effects include attenuation of hypoxic pulmonary vasoconstriction in rats, 88 cytoprotective effects against metabolic inhibition elicited by sodium cyanide and 2-deoxyglucose in ventricular myocetes of rats, 89 protection against gastropathy in rats induced by nonsteroidal anti-inflammatory drugs (NSAIDs), 90 protection against myocardial ischemia-reperfusion (MI/R), [91] [92] [93] [94] [95] [96] decrease in nociceptive responses induced by colorectal distension in rats, 97, 98 and improved survival in lethal hemorrhage in rats, 99 among many others. However, several pathological effects arising from administration of NaHS at high doses (around 10 mg/kg) have also been reported including exacerbated shock induced by cecal ligation and puncture (CLP) or by endotoxin in mouse, 100, 101 and increased stroke volume in rat models of middle cerebral artery occlusion stroke. 102 Over the years, the use of inorganic sulfide salts as exogenous hydrogen sulfide donors to study the biological effects of hydrogen sulfide continued. More recently, Wang et al. 10 and Hirota et al. 82 reported that H 2 S was found to inhibit hypoxia-inducible factor 1 alpha (HIF-1α) expression and HIF-1α-dependent gene expression. Hep3B cells were incubated at 1% O 2 for 4 hr in the presence of different concentrations of NaHS and then the expression of HIF-1α was measured by immunoblot assay. NaHS and Na 2 S were found to inhibit HIF-1α accumulation in a concentration-dependent manner in the range of 10-1000 μM. Many HIF-1α-dependent gene expression such as vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA), and pyruvate dehydrogenase kinase-1 (PDK-1) were suppressed by 50% in the presence of 100 μM NaHS. Similar effects were observed in SH-SY5Y cells, HeLa cells, HEK293T cells, and EA.hy926 cells. In 2016, Liu and co-workers reported that hydrogen sulfide generated from NaHS inhibits platelet activation and induction of thrombosis through the NOS-PECAM-1 pathway. 103 In vitro platelet aggregation studies revealed that NaHS exhibits antiplatelet aggregation effects in a dose-dependent manner. In the presence of L-NAME (10 μM), a nitric oxide synthase inhibitor, the platelet aggregation inhibitory effect of NaHS was significantly weakened suggesting that the inhibitory effect of hydrogen sulfide on platelet aggregation might be mediated by the nitric oxide signaling pathway. Furthermore, the ability for hydrogen sulfide to inhibit thrombosis was studied using the mouse deep vein thrombosis (DVT) model. It was observed that pretreatment with intraperitoneally injected NaHS (10 mmol/kg/day) in mice for 6 days followed by establishment of DVT led to a slower development of venous thrombosis compared to the control group. Western blot analyses of the endothelium of the DVT mice revealed that mice treated with NaHS showed significantly higher eNOS and iNOS protein expression than the control group. Furthermore, it was also shown that NaHS significantly elevated PECAM-1 protein content of platelets in a concentrationdependent manner suggesting that PECAM-1 may be related in the antithrombosis effect of H 2 S.
In addition to NaHS and Na 2 S, Xian and co-workers in 2016 demonstrated that the inorganic salt ammonium tetrathiomolybdate (TTM), (NH 4 ) 2 MoS 4 , slowly releases hydrogen sulfide in aqueous solution most probably as a result of simple hydrolysis. 104 Using the zinc sulfide precipitation-based MB method, it was shown that TTM (500 μM) in Phosphatebuffered saline (PBS) at different pH allowed for sustained release of H 2 S for up to 15 hr, with pH 5.0 showing the highest H 2 S release rate.
While these studies have established that inorganic sulfide salts release hydrogen sulfide and are therefore very much useful as research equivalents of hydrogen sulfide gas, their potential as viable drug candidates remains limited. The use of inorganic sulfide salts offers advantages such as convenient generation of hydrogen sulfide (as opposed to the direct use of gaseous H 2 S) and the fact that no byproducts are formed after hydrogen sulfide generation 83 ; however, these advantages are overshadowed by several critical issues. First, just as with gaseous hydrogen sulfide, the exact concentration of administered sulfide salt solution is hardly ever precisely known due to the interplay of several factors such as different levels of purity of sulfide salts used (metal ion contamination leading to oxidation and presence of extensive polysulfide contamination), 105 and volatility of hydrogen sulfide in aqueous solution. Olson and co-workers have demonstrated that hydrogen sulfide gas was lost rapidly and exponentially through volatilization and not oxidation. The half-lives range from 0.5 min to 5 min for solutions at 10 and 100 μM concentrations of Na 2 S•9H 2 O. 106 Second, bolus injection results in quick-release profiles with a spike of sulfide concentration, which may cause blood pressure to fall rapidly and thus cause detrimental effects to the patient or animal. 107 Third, hydrogen sulfide at high concentrations generated instantly from the intravenous (i.v.) administration of Na 2 S in sterile solution (IK-1001) are rapidly exhaled 108 such that their effective residence time in tissue is relatively short. 109 Last, all sulfide salts have very unpleasant odors, which presents a significant hurdle in pharmaceutical development. With all these considerations, infusion seems to be the only viable approach of administration of sulfide salts.
A phase I clinical trial was initiated to assess the pharmacokinetics of IK-1001 (an injectable form of sodium sulfide) in healthy subjects and those with impaired renal functions (Clinicaltrials.gov identifier: NCT00879645); however, this study was halted due to the lack of a rapid and reliable assay to detect sulfide concentration. After the cancellation of the other two pending phase II clinical trials (Clinicaltrials.gov: NCT00858936 and NCT01007461) due to operational decisions by the sponsoring company, there are no sulfide salt drug candidates being considered in clinical trials.
C. Natural Sulfide Releasing Compounds
In contrast to inorganic sulfide salts, some naturally occurring compounds present in several vegetables were found to generate hydrogen sulfide in a slow, but somewhat controlled manner. 87 One such vegetable is garlic, which has long been known to exhibit various biological activities such as antimicrobial, antioxidation, anti-inflammatory, cytoprotective, and cardioprotective effects. However, it was only in 2007 that the long observed cardioprotective and other health benefits derived from garlic was first linked to the biological production of hydrogen sulfide from organic polysulfide compounds present in garlic. 110 Among the studied organic polysulfides in garlic, diallyl disulfide (DADS), diallyl trisulfide (DATS), and S-allylcysteine (SAC) were found to be linked to hydrogen sulfide generation.
DADS and DATS ( Fig. 4 ) were shown to lead to hydrogen sulfide generation in red blood cells in the presence of biological thiols (i.e., glutathione) and glucose, which is necessary to maintain the reduced glutathione pools. 110 Among the garlic-derived polysulfide, those with allyl substituents and multiple sulfur atoms tethered together such as DATS and DADS were found to produce hydrogen sulfide in high quantities. It is believed that hydrogen sulfide is produced from allyl-substituted polysulfides by nucleophilic substitution by glutathione at the α carbon of the allyl substituent to generate allyl perthiol, the key reactive intermediate that subsequently undergoes another nucleophilic substitution at the S atom to give allyl glutathione disulfide andhydrogen sulfide ( Fig. 4A ). 110 To validate the link between garlic consumption and low incidence of hypertension, phenylephrine (PE) precontracted aorta rings were suspended in an organ bath, at 37°C, containing 1 mM GSH and different concentrations of the crude garlic extracts (50, 200 , 500 μg/mL). Under physiological O 2 conditions, the aorta rings exhibited concentration-dependent vasorelaxation effects. H 2 S production was observed at the same time. Upon use of specific garlic-derived organic sulfides, maximal vasorelaxation was observed with DATS and DADS. The effects coincide with the yields of H 2 S. 110 In 2015, Huang and co-workers 111 put forward chromatographic and mass spectroscopic evidence that DATS (50 μM) added to GSH (tenfold excess) generates hydrogen sulfide instantaneously both in chemical and biological settings, while DADS (purified, 100 μM) added to GSH (500 μM) does not significantly contribute to hydrogen sulfide generation through the α-carbon nucleophilic substitution mechanism as was previously reported. 111 Interestingly, while commercial DADS further purified by semipreparative High Performance Liquid Chromatography (HPLC) released small amounts of hydrogen sulfide, DADS purchased from a commercial source without further purification led to production of hydrogen sulfide. It was found through HPLC analysis that this discrepancy can be attributed to the presence of around 10% DATS impurity in commercial DADS. Such finding further emphasizes the importance of chemical tractability. Moreover, they have also put forward mechanistic evidence that hydrogen sulfide gas is generated from DATS, but not DADS. The mechanism was proposed to be through a thiol-disulfide exchange reaction ( Fig. 4B and C), not through α-carbon nucleophilic substitution as reported previously. Expected products from an α-carbon substitution was not observed while the products observed were consistent with the thiol-disulfide exchange reaction. Despite the debate regarding the possible mechanism(s) of hydrogen sulfide generation from garlic-derived polysulfides, it is clear that these polysulfides exhibit biological activities. However, the chemical tractability issue needs to be addressed in further commercial development.
It has been demonstrated that DATS administration protects the experiment subjects from MI/R injury in vivo by restoring endogenous hydrogen sulfide levels and increasing nitric r ZHENG ET AL. oxide bioavailability. 112 DATS treatment (200 μg/kg) of anesthetized MI/R injured mice led to restoration of endogenous myocardial levels of hydrogen sulfide and its stable metabolite sulfane sulfur. Administration at this concentration after MI/R injury has also been documented to prevent myocardial cell death by reducing myocardial infarct size per area at risk and per left ventricular area, and by lowering the levels of circulating troponin I after reperfusion. It was also shown that contractile function improved while preserving mitochondrial function after injury. Furthermore, endothelial nitric oxide synthase (eNOS) was found to be activated after DATS treatment and this led to a significant increase of NO bioavailability. 112 Using H 2 S-sensitive electrode for detection of hydrogen sulfide, DATS (20 μM) was found to release hydrogen sulfide at a steady rate over a prolonged period of time with maximum concentration of about 2 μM while sodium sulfide (25 μM) released hydrogen sulfide immediately with maximum concentration of about 22 μM. Since DATS releases hydrogen sulfide at lower levels and a slower rate, roughly a ten-time greater concentration of DATS is needed, relative to sodium sulfide, to achieve the same level of mitochondrial respiration inhibition. While DATS administration was linked to eNOS activation and increased NO bioavalibility, an anticipated increase in the downstream components of Nrf2 was not observed. This might have been caused by the much lower maximal concentration of hydrogen sulfide produced from DATS and the dose used in the study, which might not be enough to fully drive the Nrf2-mediated antioxidant response that was seen in previous studies. 112 Another polysulfide compound from aged garlic extracts is SAC, an organosulfur containing amino acid and a reduced form of alliin. Similar to DATS, SAC was shown to exhibit cardioprotective effects against acute myocardial infarction in rats via a hydrogen sulfide related pathway, wherein SAC serves as an additional cystathionine-γ -lyase (CSE) substrate. As a way to establish a link between the cardioprotective effects of SAC and hydrogen sulfide mediated pathways, D,L-propargylglycine (PAG), an inhibitor of CSE, was used. The administration of SAC lowered mortality to 12.5% compared to the control at 33.4%, SAC+PAG at 34.8%, and PAG only at 37.5%. Smaller infarct sizes were also observed with SAC administration while SAC+PAG and PAG-only treatments gave significantly larger infarct sizes compared to the control. Furthermore, plasma hydrogen sulfide levels after SAC administration were found to be elevated in comparison to the controls and the SAC+PAG-treated groups. Consistent with the fact that CSE is the main enzyme for hydrogen sulfide production in cardiac tissues, protein expression studies showed that SAC administration upregulated CSE expression by 1.1-fold relative to the control while SAC+PAG and PAG-only treatments downregulated CSE expression by 0.88-fold. Based on the ability for PAG to reverse the action of SAC, it was suggested that SAC depends on a CSE-related pathway to demonstrate cardioprotection. 113 However, despite these promising results, the question on how SAC generates hydrogen sulfide still remains. 114 S-propargylcysteine (SPRC), a structural analog of SAC, has been likewise shown to exhibit cardioprotective and anti-inflammatory effects by modulating endogenous hydrogen sulfide levels. 115, 116 With the goal of increasing its stability and improving hydrogen sulfide release profile, a modified SPRC, named a controlled release SPRC (CR-SPRC), was developed by using solid dispersion technique using Eudragit R RS30D as a carrier. 116 Results in an induced heart failure by ligation of left coronary artery experiment showed that CR-SPRC administration, compared to normal SPRC and positive control digoxin, improved cardiac function, reduced infarct size, and decreased myocardial fibrosis of left ventricle. These effects were correlated to hydrogen sulfide generation because the concentration of hydrogen sulfide in plasma increased significantly and that CSE expression was shown to increase by about 20%. To verify this, addition of PAG, a CSE inhibitor, led to a decrease in the plasma concentration of hydrogen sulfide and in turn reversed the cardioprotective function of CR-SPRC. Furthermore, it was also shown that antioxidant defensive molecules such as CAT, GSH, and SOD were maintained at normal levels. Further, the antiapoptopic effect of CR-SPRC was confirmed since the Bcl-2 to Bax ratio was high and caspases were found to be inhibited. 116 Aside from garlic, other vegetables have also been found to contain compounds such as isothiocyanates that are possible hydrogen sulfide donors. 117 Such suggestions were made based on the fact that the purported health benefits of these compounds are similar to that of H 2 S or other H 2 S donating drugs. 109 However, there is no direct evidence yet to support this notion. SG1002 or sodium polysulthionate is a hydrogen sulfide prodrug that is composed of 92% alpha sulfur, 7% sodium sulfate, and a mixture of long-chain sodium polythionates as the remaining portion ( Fig. 5 ). This donor was tested as an exogenous H 2 S therapeutic agent against pressure overload induced heart failure. 118 Mice with transverse aortic constriction (TAC) induced heart failure were shown to have >60% reduction in hydrogen sulfide levels. It was shown that after TAC, absence of CSE as in CSE KO mice aggravates cardiac enlargement, pulmonary edema, and left ventricular cavity dilation, while overexpression of CSE as in cardiac specific CSE transgenic mice showed sustained cardiac structure and function. These adverse effects were prevented after administration of exogenous H 2 S from SG1002. However, early withdrawal of SG1002 just after onset of pressure overload led to the development of cardiac dilatation and dysfunction suggesting that in order for SG1002 to be effective, it must be supplied throughout the follow-up period. It was also established in the study that treatment with SG1002 enhances the expression of eNOS, increases NO bioavailability, and attenuates mitochondrial respiratory dysfunction and oxidative stress. These results were correlated to SG1002's ability to activate VEGF leading to the phosphorylation of protein kinase B (Akt). Activation of Akt is then followed by phosphorylation and activation of eNOS, which then leads to increased NO and nitrite bioavailability, as well as increased myocardial cGMP. 118 Based on the cardioprotective functions exhibited by SG1002 in the previously discussed preclinical studies, a placebo-controlled dose-escalation phase I clinical trial (Clinicaltrials.gov identifiers: NCT01989208) was conducted to evaluate initial safety and maximally tolerated oral doses in humans. 119 The subjects were given oral capsules of SG1002 or placebo at doses of 200 mg, 400 mg, and 800 mg twice daily for 7 days for each dose. In the course of this study, ten adverse events were reported and resolved in healthy subjects without resorting to changes in dosing, while three adverse events (pretreatment: moderate hyperkalemia and mild upper respiratory tract infection, and treatment at 200 mg dose: mild bruising) were reported in the subjects with heart failure. There were no other clinically significant abnormalities detected based on clinical chemistry tests and vital signs measurements. Further, 400 mg and 800 mg doses in healthy subjects and 400 mg dose in subjects with heart failure showed significant elevation of hydrogen sulfide levels between 0.5 and 4 hr after administration of SG1002. This increase in H 2 S levels was sustainable in healthy subjects. A similarly sustained elevation was also observed in nitrite levels, which are indicators of nitric oxide bioavailability. In healthy subjects, the peak nitrite levels were increased after administration of 400 mg of SG1002, while in subjects with heart failure after SG1002 therapy, the peak nitrite levels increased with administration of 400 mg and 800 mg. These results indicate that SG1002 promotes nitric oxide bioavailability in healthy and heart failure patients. Analysis of B-type natriuretic peptide (BNP) and red blood cell glutathione content (indicators of cardiac health and redox status) revealed that test subjects displayed steady BNP levels and red blood cell glutathione content at all doses. As a result of the phase I studies, the project moved on to a larger placebo-controlled phase II clinical trials to further study the ability of SG1002 to reduce free radical damage. 119 All indications are that these garlic-derived polysulfur extracts have promising potential. As long as the precise ratios of the various species can be controlled, the chemical tractability issue can be addressed for process chemistry considerations. One possible concern in this regard is the consistence of composition for garlic extracts from various sources. For large-scale production and application, the quality control and assurance part for a mixture of natural products is more challenging than synthetic chemical entities. Although those garlic extracts also have issues of odor, it is not nearly as strong as hydrogen sulfide and its various salt forms, and seems to be manageable problems.
D. Lawesson's Reagent and Analogues
Lawesson's reagent (Fig. 6 ) is a phosphodithioate compound and has been an important reagent in transforming carbonyl compounds to thiocarbonyls and in the synthesis of heterocyclic sulfur compounds. This reagent can also act as a H 2 S donor through hydrolysis. 120 Studies have shown biological activity of Lawesson's reagent against various physiological and pathological conditions. In 2009, Martin et al. used NaHS and Lawesson's reagent in an effort to understand the effect of H 2 S on colitis. 121 Treatment of rats with colitis with Lawesson's reagent led to decreased severity of the colitis as measured by a decrease in colon thickness and reduced TNF-α mRNA expression, a proinflammatory cytokine. Such results suggest contributions of H 2 S donors in resolving colitis. A study conducted in 2009 showed that Lawesson's reagent could prevent ethanol-induced gastric damage in a dose-dependent manner by activating K ATP channels and afferent neurons/TRPV1 receptors. 122 In more recent times, a study was carried out by Medeiros et al. to understand the effect of Lawesson's reagent on gastric damage caused by alendronate (ALD)-a biphosphate drug used for osteoporosis and several other bone diseases. 123 ALD is responsible for mucosal damage, which could lead to hemorrhage, infiltration of inflammatory cells, and loss of epithelial cells. Rats were pretreated with saline or Lawesson's reagent (27 μmol/kg) once daily for 4 days. After 30 min, rats were administered with ALD (30 mg/kg) by gavage in order to induce gastric damage. Then rats were sacrificed 4 hr after the last administration of ALD. Gastric lesion measurements were carried out using computer planimetry and assay of gastric corpus pieces for malondialdehyde (MDA), GSH, TNF-α, IL-1β, and myeloperoxidase (MPO). Some groups were treated with glibenclamide (5 mg/kg, ip) or glibenclamide (5 mg/kg, ip) + diazoxide (3 mg/kg, ip) followed by administration of Lawesson's reagent after 1 hr and ALD in another 30 min. ALD resulted in gastric damage (ß63 mm 2 ), increased levels of TNF-1α (ß2311 pg/mL), IL-1β (ß902 pg/mL), MDA (ß121 nmol/g), increased MPO activity (ß26 U/mg), and decreased GSH levels (ß180 μg/g). Administration of Lawesson's reagent led to a decrease in gastrointestinal damage (ß16 mm 2 ), reduced TNF-1α (ß1502 pg/mL), IL-1β (ß632.3 pg/mL), MDA formation (ß78 nmol/g), reduced MPO activity (ß12 U/mg), and increased GSH levels (ß397.9 μg/g). Such results are in line with earlier findings that H 2 S reduces gastropathy induced by NSAIDs 124 or ethanol, 122 again suggesting the role of Lawesson's agent as a H 2 S donor. It was suggested that neutrophil accumulation and subepithelial edema in gastric mucosa caused by ALD might be the reason behind the formation of ulcers. Lawesson's reagent decreased ALD-induced MPO activity and TNF-α and IL-1β levels, suggesting that H 2 S donors work in protecting gastric damage by inhibition of neutrophil infiltration and neutrophil-associated TNF-α and IL-1β levels. It was suggested that ALD-induced r ZHENG ET AL. gastric damage takes place via reactive oxygen species. This was largely based on the finding that ALD decreased GSH levels and increased MDA levels. As discussed by Szabo et al., substances containing sulfhydryl radical protect the gastric mucosa in a manner similar to that of prostaglandins, and sulfhydryl blockers reverse the protective effect. 125 The study also demonstrated the mechanism of GSH inactivation of reactive oxygen species and lipid peroxidation products, resulting in attenuation of gastric damage. Thus, inhibition of the effects of ALD on GSH and MDA could be associated with the ability of H 2 S donors to decrease the redox state during ALD-induced gastric injury. In an effort to understand the mechanism through which H 2 S exerts its functions, animals were pretreated with glibenclamide, which binds and inhibits K ATP . It was found that glibenclamide ameliorated the protective effect of Lawesson's reagent, suggesting the involvement of K ATP channels in H 2 S's role in protection against ALD-induced gastric damage. 123 Even though Lawesson's reagent was found to release H 2 S, which shows pharmacological effects in various studies, there are certain properties that need improvement. For example, the H 2 S release rate cannot be controlled. This is a problem in understanding the issue of dosing schemes, among others. In addition, the poor water solubility of Lawesson's reagent and foul odor hinder its application in biological studies. Thus, there have been interests in developing analogs of Lawesson's reagent that would have improved drug-like properties. GYY4137, morpholin-4-ium-4-methoxyphenyl (morpholino) phosphinodithioate ( Fig. 7) , is a water-soluble prodrug that slowly releases H 2 S. It releases H 2 S at a sustained rate and can maintain a low concentration for a period of 7 days, in comparison to the rapid release by NaHS that peaks before 20 min and declines to undetectable levels within 90 min. 18, 126 In 2008, Moore et al. showed that GYY4137 slowly released H 2 S both in vitro and in vivo via either i.v. or intraperitoneal (i.p.) administration. 18 Specifically, GYY4137 was tested on rat aorta rings and perfused rat kidney in vitro, and in anesthetized rat in vivo. The ability for GYY4137 to dilate rat kidney and heart was examined by adding GYY4137 to perfused Kreb's solution. Responses to various agonists in the case of kidney and ventricular diastolic pressure in the case of the heart were also monitored. The effect of GYY4137 on blood pressure was studied by tail cuff plethysmography. It was found that GYY4137 resulted in a slow (onset at 10 min) and sustained (around 40 min) relaxation of the aorta ring. GYY4137 (100-500 μmol/L) caused concentration-dependent vasorelaxation, and this effect was no longer visible once the drug was removed from the perfusion solution. The reduction in blood pressure showed slow onset (observable at the 30 min point) and long duration (up to 120 min after GYY4137 administration, 26.6-133 μmol/kg). It was proposed that the vasorelaxation effect of GYY4137 was due to its release of H 2 S, which presumably causes the opening of the vascular smooth muscle K ATP channels and release of endogenous NO from endothelial cells. Such a hypothesis was based on the vasorelaxation effect of GYY4137 on the rat aortic ring and the fact that such effect was reversed by K ATP channel blockers. As a result of the vasorelaxation effect, GYY4137 showed acute as well as sustained antihypertensive effect. The slow and prolonged release of H 2 S from GYY4137 in comparison to NaHS (120 min as compared to 15-30 sec) is an important advantage from a therapeutic point of view. 18 Such results are also consistent with the release profile of GYY4137.
The concept of a narrow therapeutic window for H 2 S donors was demonstrated in a cytotoxicity experiment carried out by Deng et al. in 2011. 126 GYY4137 was tested along with NaHS and ZYJ112 (Fig. 7) , a nonsulfur containing control compound, in vitro as well as in vivo at 400 and 800 μmol/L concentrations. GYY4137 resulted in concentration-dependent killing of seven cancer lines (HeLa, HCT-116, Hep G2, HL-60, MCF-7, MV4-11, and U2OS) while having no effect on normal cell lines. NaHS (400 μmol/L) on the other hand has little effect on cell survivability and only some growth inhibition effect on HCT-116, Hep G2, and MCF-7 at high concentrations (15-30% at 800 μmol/L). Clonogenic assay results for NaHS, ZYJ1122, and GYY4137 (200-600 μM) also showed the loss of cell colonies in MCF-7 cells cultured over 10 days in the case of GYY4137, while no colony loss was seen for NaHS and ZYJ1122. The authors suggested the release rate difference as a reason for the difference in activity for the two H 2 S donors. The inactivity of ZYJ1122 against these cell lines gave evidence that H 2 S might be responsible for the observed cytotoxicity of GYY4137. Experiments were also carried out in a xenograft mouse model (HL-60 and MV4-11 cells) to understand the antitumor effect of GYY4137. A significant reduction (ß53%) in tumor size was observed in the case of GYY4137 (100-300 mg/kg/day for 14 days). It is known that high concentrations of H 2 S can have toxic effect and thus the peak concentration and release rate play an important role in determining the effect of a particular H 2 S donor. It is debatable whether one can attribute the activity of GYY4137 against cancer cells to H 2 S production. 126 Due to the slow release of H 2 S from these synthetic donors and its volatile nature, the major component that is present is the parent molecule. Therefore, the effect of the parent compound itself could not be ruled out. However, the negative results from ZYJ112 did allow for the elimination of the side product as an active component, and support the notion that the activity of GYY4137 is possibly a direct consequence of H 2 S release.
A further study of the roles of H 2 S donors based on their release rate difference was carried out by Moore and co-workers in 2010. 127 Previous studies showed that NaHS increased liver and lung MPO activities, suggesting its proinflammatory behavior. In the Moore study, murine RAW 264.7 macrophage cells were cultured, followed by addition of GYY4137 or NaHS (0-1000 μM) along with a vehicle and LPS (1 μg/mL). Assays for CBS/CSE enzymes, PGE 2 , H 2 S, IL-1β, TNF-α, IL-6, and IL-10 were performed. NaHS (0-1000 μM) showed biphasic effect on PGE 2 formation (40% inhibition at 200 μM and no effect at concentrations >500 μM), and no significant effect on NO 2 − formation at ß200 μM and biosynthesis of TNF-α and IL-1β (no inhibition of biosynthesis of the two cytokines; rather at high concentration a significant increase was observed). In contrast, GYY4137 displayed concentration-dependent inhibition of proinflammatory cytokines such as PGE 2 (IC 50 = 211 μM), NO 2 − (IC 50 = 127 μM), TNF-1α (IC 50 = 70 μM), and IL-1β (IC 50 = 134 μM), while increasing the biosynthesis of anti-inflammatory mediator IL-10 (>50% at 10 μM). These results demonstrate the antiinflammatory effects of GYY4137. 127 Thus it was concluded that H 2 S generation rate was an important factor in determining its inflammatory effects. However, the concentration difference does not explain the complete story. The duration of sustained concentrations can be an important factor.
Recently, various groups have tried to modify GYY4137 with the aim of tuning H 2 S release rate to target different disease states. In 2013, Xian's group designed O-aryl and Oalkyl substituted phosphodithioates by modification of the C-P bond of GYY4137 with Osubstitution ( Fig. 8 ). 128 Dansyl azide, 129 developed by Wang group, was used to monitor H 2 S production because of sensitivity and ease of synthesis. Out of the analogues synthesized, N,Odiarylated donors exhibited slow H 2 S release, similar to that of GYY4137 (600 nM H 2 S in 3 hr) while O-alkylated analogues showed poor H 2 S release (data not shown). These compounds were tested for their protective ability against H 2 O 2 -induced damage in H9c2 myocytes. Cells were incubated with 5a, 5b ( and then treated with 150 μM of H 2 O 2. After incubating for 5 hr, the CCK-8 assay was used to study cell viability. A 65% drop in cell viability was observed in the absence of H 2 S donors. A significant increase in cell viability was observed in the presence H 2 S donors (5a, 5b, GYY4137 and NaHS) demonstrating its protective effect against oxidative injury. GYY4137, 5a and 5b were also tested for their effect on cell growth and viability of mouse melanoma B16BL6 cancer cell line. Both 5a and 5b showed moderate toxicity, with 5b being somewhat more toxic. A notable fact was that GYY4137 was found to have the highest toxicity. Such results hint toward the role of the C-P bond in the potency of an H 2 S donor. The authors suggested linkage between the inhibition effect of H 2 S donor on B16BL6 cancer cell line and H 2 S production. Further studies would be needed in order to understand the mechanism of cell toxicity in this case. 128 Such findings are understandable because of the reactive nature of these compounds. However, the cytotoxicity of these donors could present a problem in the future development of these compounds.
In 2015, Dymock's group studied the cytotoxicity of additional GYY4137 analogues ( Fig. 9 ) against several cancer lines and W138 normal human cell line. 130 In these studies, the intracellular pH (pHi) was used as an indicator of cell viability. This was based on the fact that a reduction in pH is associated with cell death as a result of increased glycolysis leading to overproduction of lactic acid; the consequent decrease in anion and Na/K exchange causes intracellular acidification.
Compounds 6 and 7 were found to be more potent at inhibiting cell growth (IC 50 , 100-200 μM) than GYY4137 (IC 50, from 240 to >500 μM) on solid tumor cell lines MCF7, MBA-MD231, SKOV3, and PC3. At 50 μM, phosphodithioate 6 decreased pHi to 7.14 ± 0.07, while GYY4137 at the same concentration decreased the pHi to 6.75 ± 0.15. Compound 6 was also found to be more effective at intracellular delivery of H 2 S than GYY4137. For example, H 2 S concentration reached 41.5 μM when MCF7 cells were incubated with 200 μM of compound 6 for 6 hr. Under the same conditions, H 2 S concentration only reached 5.4 μM for GYY4137. Such results were attributed to the higher permeability of compound 6, which was determined to be 19 ± 5 nm/s (6 hr) and 97 ± 15 nm/s (16 hr), while GYY4137 s permeability was determined to be 1.9 ± 0.3 nm/s (6 hr) and 1.7 ± 0.4 nm/s (16 hr) . This compound also gave negative results in AMES genotoxicity test. The group also synthesized a series of analogues based on the cyclization of the initial compounds, 2,3-dihydro-2-phenyl-2-sulfanylenebenzo[d][1,3,2]oxazaphosph-oles. Compound 7, the simplest analogue with no substituent on the nitrogen, was found to be highly toxic to cancer cells. 7 also had an eightfold improved therapeutic window in W138 cells (IC 50 >50 μM) in comparison with MCF7 (IC 50 = 5.7 μM) and SKOV3 ((IC 50 = 6.12 μM) cells. Tests done on MCF7 solid tumor cells showed that 7 inhibits spheroid growth by about 70% after 14 days at 100 μM concentration. Increase in cleaved Poly (ADP-ribose) polymerase (PARP) and activated caspase-7 suggested that cell death occurs via apoptosis. These compounds are being explored for development of cancer therapeutics. 130 Though the above-mentioned H 2 S donors show good biological activity, it is still not known whether their activity can be entirely attributed to the release of H 2 S or the biological activity of the molecule itself. Given the slow rate of release of H 2 S from these phosphodithioate molecules, the major species in the medium is the parent molecule, not H 2 S. Since phosphodihtionates are found to be biologically active compounds, it is difficult to pinpoint the activity of the above-mentioned analogues to the release of H 2 S. More extensive experiments need to be performed in order to understand the mechanism(s) behind the pharmaceutical role of these H 2 S donors. However, this would be true for most prodrug approaches unless one can unambiguously demonstrate the principal active component. Another point that needs to be considered is how to ameliorate the pungent smell of such compounds in order to increase the chance of eventual success. 131
E. Thioamides
In 2013, Calderone and co-workers prepared a small library of arylthioamides and evaluated their H 2 S-releasing properties. 132 They identified p-hydroxybenzothiomide 8 as the lead compound and made several modifications such as the introduction of different functional groups (9) (10) (11) (12) (13) , replacement of the p-hydroxy group with an amino group (14) , and replacement of phenyl ring with electron-poor and electron-rich heterocycles (15) (16) (17) (18) (19) (Fig. 10) . Compounds 8-19 at 1 mM concentrations were incubated in PBS buffer at physiological pH and temperature. Then, amperometric approach using H 2 S sensitive minielectrodes and free radical analyzer as detector was used to characterize the potential of these compounds to release hydrogen sulfide. With literature precedence identifying organic thiols such as reduced glutathione as a requirement for hydrogen sulfide generation in some hydrogen sulfide donors, the effect of adding 4 mM of L-cysteine was also part of their experiments. Their results revealed that these arylthioamides have different hydrogen sulfide releasing rates and probably release hydrogen sulfide through different mechanisms. It was found that compounds 8-10 and 14 released low levels of hydrogen sulfide (<2 μM) when incubated without L-cysteine, but showed significantly higher levels of hydrogen sulfide in the presence of L-cysteine. In contrast, compounds 11 and 12 released low levels of hydrogen sulfide (<2 μM) both in the absence and presence of Lcysteine. Compound 13 was able to release hydrogen sulfide both in the absence and presence of L-cysteine. On the other hand, analogues 15-19 exhibited mixed results. Especially noteworthy is that 16, 17, and 19 showed high L-cysteine-independent hydrogen sulfide generation. These results suggest that arylthioamides release hydrogen sulfide either through thiol activation 30 or through simple and spontaneous hydrolysis.
Following confirmation of H 2 S release from arylthioamides, compound 8 was further used in subsequent pharmacological studies. First, it was shown that pretreatment of aortic rings with compound 8 at 1 mM concentration almost completely abolished the vasoconstriction induced by noradrenaline. It was also shown that about 0.2 μM of hydrogen sulfide was detected after incubation of compound 8 for 15 min in the presence of biological samples such as aortic rings, while almost no hydrogen sulfide was detected in the absence of aortic rings. Such results could be explained in many ways. One way of looking at this is that hydrogen sulfide generation from compound 8 does not require exogenous L-cysteine or thiols in the biological setting since the amount of organic thiols present in the biological sample such as that of aortic rings is enough to ensure release of hydrogen sulfide. Furthermore, it was shown that administration of compound 8 hyperpolarized the membrane of human vascular smooth muscle cells in a dose-dependent fashion. The maximal hyperpolarization induced by 1 mM of compound 8 was around 79% while that of NaHS was only around 52%. Finally, oral administration of 0.1 mg/kg NaHS and compound 8 to normotensive rats both led to a significant reduction of systolic blood pressure by about 90%.
These findings make arylthioamides promising H 2 S donors for further studies. Calderone et al. reported that incubation of 1 mM of the donors only released H 2 S with a C max value of about 10 μM, making the H 2 S donor the dominant species in solution. Thus, the relationship between the observed bioactivities and the generation of H 2 S is not unambiguously demonstrated, and it is entirely possible that the bioactivities were caused by the donor itself or a combination of various species. This issue is quite common among the organic H 2 S donors. In order to properly understand the mechanism of H 2 S release and bioactivity, further studies are necessary. In those cases, the availability of appropriate controls would be very useful.
In 2014, Calderone et al. 133, 134 reported aryl isothiocyanate derivatives as another type of slow release H 2 S donors ( Fig. 10 ). Thiol activation for these donors was also necessary. Although the mechanism of action of isothiocyanate is still unclear, some lead compounds, such as isothiocyanatobenzene and 4-isothiocyanatobenzoic acid were characterized and reported to possess vasorelaxing effects on coronary conductance arteries. One may presume that aryl isothiocyanates react with cysteine to form thioamide derivatives, which are known H 2 S donors.
Along with these thioamides analogues being well studied, thioamide hybrid drugs were also investigated. It was reported that H 2 S reduced visceral pain. [135] [136] [137] In a clever design of a hybrid drug, Aptalis Pharma reported GIC-1001 ( Fig. 10) , 138 a protonated form of trimebutine that uses 3-thiocarbamoylbenzenesulfonate as the anion capable of releasing H 2 S. In a recent study, both GIC-1001 and its parent drug trimebutine were tested in a mouse model (C57Bl6 male mice, 6-8 weeks) of colorectal distension. 139 Oral administration of GIC-1001 (30 and 60 mg/kg) was able to significantly reduce nociceptive response to all noxious stimuli, in a dose-dependent manner, while oral treatment of equimolar doses of trimebutine (25 and 50 mg/kg) only showed slight effects. Now known as a colonic analgesic drug candidate, GIC-1001 is proposed as an alternative to parenteral sedation modalities currently used in colonoscopy. This compound is a dual-action, single molecule that offers both the spasmolytic and colonic peripheral opioid agonistic activity of trimebutine as well as the antinociceptive effects of H 2 S. GIC-1001 is a new molecular entity that was found to be safe and well tolerated when first administered to humans. The addition of H 2 S-releasing counter ion (3thiocarbamoylbenzenesulfonate) to trimebutine did not affect the safety profile of trimebutine. 140 Many studies have shown that thioamides and its derivatives were potential H 2 S prodrug candidates; however, there are still some issues that are worth discussing. First, to achieve certain micromolar concentrations of H 2 S, millimolar concentrations of thioamides are usually required. Such high concentrations of substrates might cause many other issues, such as toxicity, solubility, and interference with biological components. Second, because of their uncontrolled release mechanisms, H 2 S dose-dependent effects might be subjected to many possibly perturbing factors. Third, the stability of prodrugs are also needed to be taken care of, especially in sample preparation process.
F. 1,2-Dithiole-3-Thiones and H 2 S Hybrid NSAIDs
1,2-Dithiole-3-thiones (DTTs) have been well characterized and are known to release H 2 S. Although, the H 2 S release mechanism of DTTs is still to be elucidated, previous studies suggested that hydrolysis of DTTs yield H 2 S in aqueous buffer (Fig. 11 ). This could qualify DTT as a hydrolysis-based H 2 S donor. 141 Along this line, Li et al. found that H 2 S release from DTT is a result of hydrolysis. 142 Owing to the side effects of NSAIDs such as gastrointestinal ulceration and bleeding, [143] [144] [145] and the anti-inflammatory effect of H 2 S, there have been interests in developing H 2 S-NSAID hybrids to reduce side effects. Thus, DTTs have been conjugated to NSAIDs to form H 2 S-NSAIDs hybrid (H 2 S-NSAIDs, Fig. 12 ). In 2007, Fiorucci et al. 146 reported ATB337, a diclofenac-DTT hybrid prodrug. Compared with its parent drug, ATB337 showed significantly reduced gastrointestinal damage without compromising antiinflammation efficacy. In a rat model, 3 hr after oral administration of ATB337 at 50 μmol/kg, a 40% increase of serum H 2 S concentration, in comparison with vehicle or diclofenac alone, was observed. Oral administration of diclofenac (50 μmol/kg) led to significant hemorrhagic gastric erosion, small intestinal ulceration, and ICAM-1 mRNA and LFA-1 mRNA expression upregulation, indicating gastrointestinal damage. When 50 μmol/kg of ATB337 was orally administrated, no obvious hemorrhagic gastric erosion, small intestinal ulceration, ICAM-1 mRNA and LFA-1 mRNA expression upregulation were observed in comparison. It was also found that ATB337 had no effect on leukocyte adherence in postcapillary mesenteric venules in the rat at 50 μmol/kg dosage, while diclofenac led to a significant increase in leukocyte adherence. Together with its ability to mitigate gastrointestinal damage, ATB337 has similar anti-inflammation efficacy as diclofenac. In a rat model of inflammation induced by zymosan, both ATB337 and its parent drug inhibited COX-2 activity by more than 95% at a dose of 10 μmol/kg. Another HS-NSAID hybrid prodrug-ATB-343 was investigated by Wallace. 147 ATB-343 is a hybrid of ADT-OH and indomethacin and was found to exhibit improved efficacy and reduced gastrointestinal damage compared with indomethacin.
NSAID conjugates such as H 2 S-sulindac (H 2 S-SUL), H 2 S-aspirin (H 2 S-ASA), H 2 Sibuprofen (H 2 S-IBU), and H 2 S-naproxen (H 2 S-NAP) were reported to have antiproliferative r ZHENG ET AL. Medicinal Research Reviews DOI 10.1002/med effect against human colon, breast, pancreatic, prostate, lung, and leukemia cancer cell lines. 148 HT-29 cells were treated with different concentration of the drugs for 24 hr, followed by proliferating cell nuclear antigen (PCNA) quantification. H 2 S-ASA, H 2 S-NAP, H 2 S-SUL, and H 2 S-IBU reduced proliferation in a dose-dependent manner, as measured by the expression of PCNA. They were also found to have growth inhibitory effect. In a growth inhibition study, H 2 S-ASA was found to be at least 3000-fold more potent than ASA in A549 lung cancer cells.
Although the antiproliferation effect could be explored along the lines of cancer treatment, for treating inflammation this would be considered toxicity. Thus for different applications, the way to optimize these compounds would be different. Some known pharmaceutical molecules like L-3,4-dihydroxyphenylalanine (L-DOPA for treatment of Parkinson's disease (PD) and dopamine-responsive dystonia) have also been conjugated to DDTs. Studies revealed that some side effects (such as the development of dyskinesia) after long-term use of L-DOPA may be caused by the loss of neurons induced by oxidative stress. 149 H 2 S is well known to reduce oxidative stress. 150 Therefore, L-DOPA coupled with a H 2 S donor might reduce the toxicity of L-DOPA. Along this line, McGeer et al. synthesized a library of DOPA-DTT conjugates and evaluated their antioxidant effects. 151 There is a 90% decrease in GSH level in SH-SY5Y cells after 1 day treatment of THP-1 or U373 conditioned medium; however, pretreatment with 10 μM of ACS84 for 8 hr followed by THP-1 or U373 conditioned medium led to a significant increase of GSH level compared with L-DOPA-treated group. The increase of GSH presumably results from the H 2 S generated from the donor moiety. These data demonstrate that L-DOPA hybrids may have antioxidant therapeutic potential by increasing GSH levels. Previous studies have indicated that H 2 S is a reducing agent that can increase levels of intracellular glutathione thereby inhibiting oxidative stress. 152 It also decreases levels of peroxynitrite-derived nitrated proteins. 153 Yet there are other studies that seem to suggest a role for the direct scavenging of free radicals by H 2 S. 154 Thus H 2 S might block oxidative stress-mediated cell death in PD by indirectly detoxifying free radicals generated from oxidized L-DOPA compounds.
Additionally, Kashfi et al. reported NSAID-based hybrid anticancer compounds 155 including NBS-1120 ( Fig. 12A) , which could release NO, H 2 S, and aspirin at the same time. NBS-1120 inhibited HT-29 colon cancer growth with IC 50 values of about 46, 20, and 8 nmol/L at 24, 48, and 72 hr time points, respectively. Szabo et al. developed AP39 by coupling ADT-OH with triphenylphosphine (TPP) to give mitochondrion-targeted H 2 S donors (Fig. 12A ). 156 The presence of AP39 in mitochondria was confirmed by several fluorescent probes. 157 The effects of AP39 on bioenergetics, viability, and mitochondrial DNA integrity were investigated. Incubation of AP39 (100 nmol/L) with bEnd.3 murine microvascular endothelial cells caused an increase in basal oxygen consumption rate (OCR), which is equivalent to the respiratory reserve capacity (a major bioenergetic parameter). At an increased concentration of AP39 (300 nmol/L), an inhibitory effect was observed instead. 156 AP39 could also attenuate the loss of cellular bioenergetics during oxidative stress caused by glucose oxidase and protect against oxidative mitochondrial DNA damage.
More recently, Hasegawa and Van Del Vlies 158 (Fig. 12A ) developed DTT-based polymeric H 2 S donors by conjugating DTT to poly(ethylene glycol) polymers (PEG-ADT) to improve its water solubility.
In 2016, Liu et al. 19 demonstrated that exogenous H 2 S (NaHS) attenuates doxorubicin (DOX) induced cytotoxic effects in H9c2 cardiac cells through the PI3K/Akt/FoxO3a pathway. During the same period, Chegaev et al. 159 reported a series of H 2 S-releasing doxorubicin analogs (H 2 S-DOXs) by combining DOX with an appropriate H 2 S donor substructure (Fig. 12B) . These H 2 S-DOXs were used to test for the effect of increasing degrees of DOX resistance in H9c2 cells, U-2OS osteosarcoma cells, and related cell variants. It showed that H 2 S-releasing moieties r ZHENG ET AL. strongly influenced the products' biological activities. In addition, they found that H 2 S-DOX-10 and 11 did not produce a significantly higher level of toxicity than the lead compound on H9c2 cells. However, they displayed significantly more potent cytotoxicity than those of the lead on sarcoma cell lines. Preliminary studies carried out on H 2 S-DOX-10 suggest that the increased cytotoxicity is likely due to a reduced efflux of the product by P-glycoprotein (Pgp), which is a membrane transporter that pumps DOX out of the cell and limits its anticancer effect. 160 Although the H 2 S release mechanism from DTT has not been fully characterized, its bioactivity has been well studied in vitro and in vivo. The H 2 S-NSAID showed promising therapeutic potential and allowed for oral administration. Owing to its relatively stable feature, targeted delivery can also be achieved. These prodrugs represent a very promising direction of research and development. However, in terms of delivery and developability issues for these H 2 S prodrugs, there are several points that are worth discussing regarding the DTT and its NSAIDs hybrids. First of all, the stench odor of these compounds is still an obstacle for further development. Second, the persulfide reactivity, especially as part of a thioamide group could become an issue later on because of its highly reactive nature. Third, the ability to precisely define the release profile of these prodrugs will aid the further development. Fourth, the chemical stability of DTT and their persulfide versions need to be carefully examined for chemical tractability considerations.
G. Thiol-Activated H 2 S Donors
The general strategy of current thiol-activated H 2 S release approaches is the usage of unstable thiol species such as perthiol or gem-thiol caged by protecting groups. The protecting groups should stabilize the active thiol species enough to be synthesized, purified, and stored for a long period but are ready to be selectively removed in the presence of certain activators in the biological environment. Thus far, the acyl group has been commonly used as the protecting group, which is stable enough for preparation and storage, but active enough to be removed when free thiol species are applied as the activator because of its strong nucleophilicity.
In 2010, Xian's group reported a new H 2 S donor system N-mercapto-based H 2 S donors (NSHDs), a design that takes advantage of the instability of the S-N bond. 161 These NSHDs utilize free thiol species as specific activators and have tunable release rates. Specifically, the thiol group is stabilized by an acyl group, which can be selectively activated by a free thiol group without interference by other nucleophiles (Fig. 13 ). The exchange with a free thiol species such as cysteine or GSH leads to the collapse of the prodrug, which generates S-acylated cysteine as the side product and N-mercaptobenzamide. Cysteine would attack the N-mercaptobenzamide to form the perthiol as the key intermediate. Further reaction of the perthiol species with cysteine would release H 2 S. Tunable release rates can be achieved by modifications of the thioester moiety. 162 Structure-activity relationship (SAR) studies uncovered that thioester moieties of the donors with less electron density showed faster H 2 S release; those with more hindered substitutions showed slower release rates. The H 2 S release efficiency was tested by the MB method in PBS buffer (pH 7.4) with 10% Tetrahydrofuran (THF) in the presence of 1 mM of cysteine. At 100 μM, the donors can release H 2 S with a peak concentration of 20-55 μM at the time point of 45-80 min. Mechanistic studies of the NSHDs revealed that perthiol can be a very useful intermediate for the generation of H 2 S.
To validate the biological effect, the protective effect of these prodrugs against MI/R injury was tested in a murine model system. 162 Mice were subjected to 45 min of left ventricular ischemia followed by 24 hr of reperfusion. Then H 2 S donors or vehicle were applied by direct intracardiac injection at the time of reperfusion. Compared with vehicle alone, treatment group showed reduced infarct size per area at risk (INF/AAR). NSHD-1 and NSHD-2 (100 μg/kg) maximally reduced INF/AAR by 35% and 50%, respectively. There was also a signif- icant reduction of circulating cardiac troponin I levels when treated with NSHD-2 at 50 and 100 μg/kg.
NSHDs were also shown to protect human skin keratinocytes against methylglyoxal (MGO) induced injury in vitro. 163 HaCaT cells, a human skin keratinocyte cell line, were treated with MGO (50-600 μM) for 48 hr, leading to concentration-dependent decrease in cell viability. Cells pretreated with 50-200 μM NSHD-1 and cysteine for 1 hr followed by treatment of 400 MGO for 48 hr showed concentration-dependent enhancement in cell viability compared with those treated only with MGO.
In 2013, another H 2 S donor, tertiary perthiol-based H 2 S, was designed by Xian's group. 164 The mechanism of sulfide release is shown in Figure 14 . Briefly, the attack of thioester by free thiol species would release the perthiol. The perthiol is vulnerable to free thiol species and would directly release H 2 S or generate another perthiol, which would go through the same process and release H 2 S eventually. The tertiary perthiol-based H 2 S donors also showed similar cardioprotective activity as NSHDs. In 2013, Galardon's group discovered another class of H 2 S donor: dithioperoxyanhydrides, using perthiol as a key intermediate and with a similar mechanism as the perthiol H 2 S donor mentioned above. 165 The mechanism is shown in Figure 15 . In the presence of 5 mM cysteine, a peak concentration of 20 μM of H 2 S was achieved from 50 μM of the donor. This donor was found to be able to induce concentration-dependent relaxation of isolated rat aortic rings with an EC 50 of 5.2 μM.
Another class of thiol-activated H 2 S donor is based on gem-dithiols. 166 The mechanism of sulfide release is shown in Figure 16 . Gem-dithiols are not stable species and would release H 2 S upon decomposition. However, protection with an acyl group allows these compounds to be stable enough. Once selectively deprotected by a free thiol species, the resultant gem-dithiols would collapse and generate H 2 S. By changing the substitution of the phenyl ring, tunable release rates can be achieved. The H 2 S release ability was tested by the MB method in PBS buffer (pH 7.4) with 10% THF. At 100 μM, the donor was able to release H 2 S with a peak concentration of 25-94 μM in the presence of 500 μM of cysteine. This donor did not induce cytotoxicity in HeLa cells in the range of 5-25 μM.
More recently, Matson et al. developed a series of thiol-activated polymeric donors. 167, 168 These donors have a slower release rate and thus allow for sustained H 2 S concentrations. When the peptide-based H 2 S donor gels were incubated in aqueous solution in the presence of 1 mM of cysteine, 100 μM donor generated a peak concentration of 5.5 μM at the 110 min point and H 2 S was still detectable after 15 hr. The author pointed out that slower release rate might be caused by the limited penetration of cysteine through the peptide gel.
These thiol-activated H 2 S donors have tunable release rates and specific activators with clear release profiles. Thus they are excellent research tools and potential therapeutic agents. Some of their therapeutic effects were well-studied both in cell culture and animal models. However, there are few potential issues that need to be addressed. First, the real biological system is rather complex and the perthiol generated can interfere with redox-active biomolecules leading to perturbation of the redox balance. This will need to be taken into consideration in evaluating potential applications. Second, these prodrugs rely on free thiol species as the activator (usually five or more equivalents). The release process could be hindered by a lack of free thiol species. Thus a good understanding of fluctuation of free thiol concentrations in vivo is important in crafting dosing schemes and analyzing potential pitfalls. Third, the perthiol species may have its own activity and the lack of well-defined negative control make it hard to determine what the "active principal" is. It is also possible that the independent activity of perthiol might be an advantage in eventual applications. Nevertheless, it will be important to deconvolute this issue. 
H. Photosensitive H 2 S Donor
In 2013, Xian's group designed a photo-induced H 2 S donor, which takes advantage of the ability of gem-dithiols to release H 2 S. 169 The mechanism of release is shown in Figure 17 . The unstable gem-dithiols was protected by a light-sensitive group (2-nitrobenzyl group), and upon UV irradiation, the gem-dithiols were liberated, leading to spontaneous release of H 2 S by hydrolysis. The H 2 S releasing ability was confirmed by the MB method and a fluorescent probe WSP-1. Two hundred micromolar of the prodrug in PBS (pH 7.4)/acetonitrile (1:1) was shown to generate a peak concentration of 36 μM of H 2 S at the 7 min point after UV irradiation (365 nm).
In 2014, Nakagawa's group designed another photosensitive H 2 S donor, ketoprofenate caged H 2 S donor (SPD-1). 170 As shown in Figure 18 , upon UV exposure (300-350 nm), one equivalent of H 2 S was released, accompanied by two equivalents of 2-propenylbenzophenone and CO 2 . The H 2 S releasing ability was dependent on both the irradiation time and intensity. In HEPES buffer (pH 7.4) with 1% Dimethyl sulfoxide (DMSO), after exposure to a light intensity of 5.1 mWcm −2 for 200 sec, a peak concentration of 18 μM was achieved from 100 μM of the prodrugs. In 2015, another photosensitive H 2 S donor-SPD-2 was designed by Nakagawa's group with improved photochemical properties. 171 SPD-2 allowed to be activated with longer wavelength (325-385 nm). In PBS buffer (pH 7.4) with 1% DMSO, after exposure to a light intensity of 2.0 mWcm −2 for 400 sec, 47 μM H 2 S was detected by MB method from 100 μM of the prodrug. The photo-induced H 2 S donors are wonderful research tools. However, their cytotoxicity and the limited penetrability of light pose an issue in their application as pharmaceutical agents. Besides, there are only limited options for chemical modifications to tune the UV-cleavage and hydrolysis rate. Compared with the thiol-activated H 2 S donors, the release efficiency is much lower. In addition, there will be a need to consider the reactivity of the byproduct 2-nitrosobenzaldehyde with H 2 S and many other nucleophiles in the biological environment.
I. Thioamino Acid
In 2012, Giannis's group described thioamino acids as H 2 S donors in the presence of bicarbonate under physiological environment. 172 The thioamino acid would first react with bicarbonate to form the carbamate intermediate ( Fig. 19 ), which would go through cyclization to generate N-carboxy-anhydride with the concomitant release of H 2 S. The time-and temperaturedependent H 2 S release of thioglycine in the presence of 40 mM bicarbonate was determined by NMR. 172 While thioglycine was stable at 25°C, slow decomposition was observed at 40°C and an equilibrium was obtained after 72 hr with 35% conversion in a sealed system. The H 2 S release ability was also evaluated in vivo and the H 2 S concentration was determined by a fluorescent probe, dibromobimane. After i.p. injection of 5 mg/kg of thioglycine, H 2 S concentration increased in the rat plasma in a time-dependent manner, leveling off at 35 μM after 2 hr. The vehicle group remained stable with H 2 S concentration at 10 μM. The biological activity of this H 2 S donor was assessed by its ability to increase intracellular cGMP levels. Treatment of 300 μM thioglycine led to a tenfold increase of cGMP level in smooth muscle cells, while NaHS only led to a twofold increase at the same concentration. Thioamino acid based H 2 S release systems show good H 2 S releasing ability and solubility. However, the release rate is almost fixed because there is not much room for chemical modifications and carbonate concentrations under physiological conditions are not easily manipulated for release purposes.
J. Enzyme-Sensitive H 2 S Donors
In 2016, Wang's group developed enzyme-sensitive H 2 S prodrugs. 77 The mechanism is shown in Figure 20 . In this case, H 2 S was caged as a thioacid and a nucleophile (hydroxyl group) was masked with an acyl group as the protecting group. Upon ester hydrolysis by esterases, the free hydroxyl group generated can initiate a lactonization reaction with the thioacid to release H 2 S. The control compounds (iHPs) have a free carboxylic acid, which releases H 2 O upon lactonization, instead of hydrogen sulfide. Time-dependent H 2 S release from the prodrug system was documented by using a H 2 S-selective microelectrode. For BW-HP-101, in the presence of 1 unit/mL porcine liver esterase (PLE), 200 μM prodrug in PBS (pH 7.4, 1% DMSO) at 37°C resulted in a peak H 2 S concentration of about 95 μM at the 15 min point. H 2 S release was also validated by a widely used H 2 S fluorescent probe WSP-5. In the presence of PLE or fetal bovine serum (FBS) in PBS, strong fluorescence was detected after incubation, while PBS alone did not lead to fluorescence enhancement, suggesting its stability without the esterase. Through modification of the protecting group and the lactonization rate, tunable release rates were achieved. When prodrugs (200 μM) were incubated in PBS with 1 unit/mL esterase at 37°C, their half-lives ranged from 13 to 99 min with the H 2 S peak concentration varying from 95 μM to 13 μM. The ability for these prodrugs to inhibit TNF-α expression in macrophages exposed to lipopolysaccharide (LPS) was evaluated. Thus RAW 264.7 cells were cotreated with HPs or iHPs, 1 unit/mL esterase and 1 μg/mL of LPS for 1 hr. All the H 2 S prodrugs at 50 μM showed significant inhibition of LPS-induced TNF-α production while iHPs showed no effect. In the meantime, Na 2 S at the same concentration led to an obvious increase in the production of TNF-α.
H 2 S is known to alleviate gastric damage, which is the common side effect of NSAIDs because of their inhibition of cyclooxygenases 1 (COX-1) and irritation feature of the carboxylic group. 141 Therefore, conjugates of a H 2 S prodrug with NSAIDs has promising therapeutic applications as described earlier. 173 The esterase-sensitive prodrugs from Wang's lab were conjugated to NSAIDs (Fig. 21) . Specifically, BW-HP-105 was synthesized and its release kinetics was examined by HPLC. The hybrid prodrug showed a slower release rate (half-life about 2 hr) than the parent prodrugs, as expected. The tunable release rate with well-defined H 2 S release profile and the easily performed negative control make these prodrugs powerful tools in the study of H 2 S-NSAID hybrid prodrugs.
These esterase-sensitive H 2 S prodrugs are odorless white solid and show good water solubility (10 mM in aqueous buffer), stability (no obvious decomposition at room temperature for 3 days and −20°C for several months), and lack of cytotoxicity at up to 200 μM. The easy chemical modification of the protecting group and the substitutions essential for the lactonization can lead to hundreds of analogs with different release rates. The release trigger is an esterase, which is ubiquitous in the biological environment. However, the thioacid group is both a good nucleophile and electron donor, which may interfere with biomolecules. Additional biological evaluation is needed to assess the true potential of these prodrugs.
K. pH-Controlled H 2 S Donors
In 2016, Xian and co-workers reported pH-sensitive H 2 S prodrugs based on phosphorothioate. 174 These prodrugs were designed to address the issues of GYY4137, such as H 2 S release rate being too slow and uncertain mechanism. The mechanism is shown in Figure 22 . Under acidic conditions, a nucleophilic carboxylate is proposed to attack the phosphate center to form a stable five-membered ring, leading to the release of H 2 S. The H 2 S release ability was validated by a modified zinc sulfide precipitation-based MB method. These donors showed a pH controlled release pattern. At pH 5.0, 100 μM JK-1 (Fig. 23) can generate a H 2 S peak concentration of about 50 μM within 20 min and at pH 8.0, no detectable H 2 S was produced. Compared with JK-1, the introduction of a benzyl group at the α-position leads to a faster r ZHENG ET AL. release rate. No cytotoxicity was observed up to 400 μM after 1 hr incubation in H9c2 and HeLa cells. The protective effect of these prodrugs against MI/R injury was tested in a murine model. Mice were subjected to 45 min of left ventricular ischemia followed by 24 hr reperfusion. Then H 2 S donors or vehicle was applied by direct intra cardiac injection at time of reperfusion. Compared with the vehicle alone, treatment group showed reduced INF/AAR. A total of 100 μg/kg JK-1 and JK-2 ( Fig. 23 ) maximally reduced INF/AAR by 64% and 56%, respectively. There was also a significant reduction of circulating cardiac troponin I levels when treated with JK-1 and JK-2 at 100 μg/kg compared with those that did not receive H 2 S drug treatment. These acid-promoted H 2 S release donors can be attractive therapeutic reagents for MI/R injury, which often results in decreased local pH.
L. Carbonyl Sulfide Based Donors
In 2016, Pluth and co-workers reported a hydrogen sulfide donor based on the self-immolative cascade decomposition of benzyl thiocarbamates to release carbonyl sulfide (COS), which is, in turn, hydrolyzed by the enzyme carbonic anhydrase (CA) to hydrogen sulfide (Fig. 24 ). 175 This donor was designed in such a way that the reduction of the azide moiety by tris(2carboxyethyl)phospine (TCEP), a fast-acting azide reducing agent, to the amino group serves as the trigger for the self-immolation leading to the extrusion of COS. Using 1 H, 13 C, and 19 F NMR spectroscopy to monitor the reduction, it was confirmed that the benzyl thiocarbamate scaffold undergoes rapid self-immolation within 5 min of TCEP addition. It was demonstrated that incubation of this donor with CA alone without TCEP does not lead to hydrogen sulfide generation. Furthermore, to verify the role of CA, the addition of CA inhibitor acetazolamide at 2.5 μM significantly reduced the rate of H 2 S production. To substantiate that the thiocarbamate moiety is essential to the production of hydrogen sulfide, an analogous carbamate scaffold was also incubated under identical conditions wherein hydrogen sulfide generation was not observed. Using whole mouse blood and excess TCEP, it was found that a thiocarbamate analog without the azide moiety trigger was stable in whole blood and that the total sulfide concentration as measured by the monobromobimane method was at 8 μM, which is approximately the same as that of the background levels in murine blood. On the other hand, the thiocarbamate analog with the azide moiety trigger increased the total sulfide concentration to around 18 μM.
These findings indicate that this hydrogen sulfide donor is stable in the biological setting and that even significantly lower levels of endogenous CA as is observed in the murine blood can still hydrolyze COS released after the triggered self-immolation of the benzyl thiocarbamates.
Another hydrogen sulfide donor based on the hydrolysis of COS was reported by Matson et al. 176 The design was based on the ring-opening polymerization of N-thiocarboxyanhydrides (NTA) by biological nucleophiles such as glycine to release COS with peptides as byproducts ( Fig. 25 ). COS, in turn, is converted to H 2 S either by CA or by simple hydrolysis. Using the MB assay in the presence of 300 nM CA and 1 mM glycine in PBS buffer (pH 7.4), it was found that the pseudo-first-order release half-life of H 2 S for the small molecule NTA is 75 min while that of polymeric NTA (using 100 μM glycine) is 280 min. The ability of these donors to deliver H 2 S in a biological system was tested using brain-derived endothelial cells. It was found that cells treated with the small molecule NTA (100 μM) exhibited enhanced rates of endothelial cell proliferation while enhancement was not observed using the polymeric donor.
Indeed this platform for hydrogen sulfide donation is new, versatile, and amenable to modifications. However, more studies in both chemistry and biology are needed. For instance, the validation of the suitability of the use of excess TCEP in the biological setting as the trigger for the self-immolation of the benzyl thiocarbamates.
CONCLUSIONS
With the demonstrated therapeutic potential of H 2 S, there have been increased interests in developing its donors, which allow for controlled release. As with the development of small molecule drugs, there are developability issues that need to be considered. In addition to the commonly recognized developability issues related to absorption, distribution, excretion, metabolism, and toxicity, there are also unique issues related to gasotransmitters. For example, the dosage question is not only a concentration issue, but also involves release rates. In terms of chemistry properties, H 2 S is both a good nucleophile and strong reducing reagent, which poses additional challenges in drug delivery. Unique to H 2 S is also the issue of odor. For widespread applications, masking the unpleasant odor of H 2 S is essential.
In addition to these clearly identifiable issues, there are also more challenging problems. For example, it has been widely accepted that H 2 S has a very narrow therapeutic window. To complicate this, H 2 S can be easily converted to various species at different oxidation states, which may each possess their own biological activities. Furthermore, the volatility of hydrogen sulfide makes concentration control difficult. For example, half of the dose of H 2 S could be lost in 5 min from open cell culture wells. 106 H 2 S concentration can decrease so rapidly that the precise measurement of H 2 S concentration is a great challenge in this field. 76, [177] [178] [179] [180] All these concentration-control issues may further exacerbate the narrow therapeutic window issue and make the clinical development of H 2 S very challenging.
Although, most of the possible therapeutic indications of hydrogen sulfide have been studied in the context of cytoprotection, treatment of cardiovascular conditions, and alleviation of oxidative stress, there have also been explorations of using hydrogen sulfide donors for r ZHENG ET AL.
treating cancer, largely due to the cytotoxicity of some of these hydrogen sulfide prodrugs. One cautionary note in doing so is to make clear the distinction in the difference of the "bar" used in examining cytotoxicity. If one is looking at cytotoxicity as an undesirable property, which is the case most of the time in drug discovery and development, then IC 50 values in the high micromolar range is considered sufficiently cytotoxic to be of concern. On the other hand, if one is to explore cytotoxicity for the development of anticancer compounds, then the bar is at least at the level of doxorubicin in terms of IC 50 (single digit micromolar or submicromolar range depending on cell lines used). In addition, the anticancer field is moving more and more away from simple cytotoxic agents toward mechanism-based targeted therapy. Thus understanding the mechanism of action and examining whether the anticancer effect could be used in targeted therapy will be very important. We hope that raising these issues will help guide future research work in the direction that would aid the eventual development of H 2 S-based therapeutics.
